Vasoactive Peptide Pharmacology

Correct Answer

C — Angiotensin receptor blocker

Rationale

Candesartan is an angiotensin receptor blocker. It was the agent studied in the CHARM-Alternative trial, which established angiotensin receptor blockers as guideline-endorsed alternatives to angiotensin-converting enzyme inhibitors in heart failure with reduced ejection fraction. Other angiotensin receptor blockers include losartan, irbesartan, valsartan, telmisartan, and olmesartan. Aliskiren is the direct renin inhibitor. Sacubitril-valsartan is the only approved angiotensin receptor-neprilysin inhibitor.

Correct Answer

A — Angiotensin receptor-neprilysin inhibitor

Rationale

Sacubitril-valsartan is classified as an angiotensin receptor-neprilysin inhibitor, abbreviated ARNI. It is a fixed-dose combination of two pharmacologically distinct components: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin receptor blocker. This dual mechanism gives the combination its class name. It is not an angiotensin-converting enzyme inhibitor — in fact, combining sacubitril-valsartan with an angiotensin-converting enzyme inhibitor is absolutely contraindicated because of additive bradykinin accumulation and angioedema risk.

Correct Answer

B — Losartan

Rationale

Angiotensin receptor blockers, including losartan, are classified as pharmacologically active as administered — they do not require hepatic conversion to produce their therapeutic effects. This contrasts with sacubitril, which is a prodrug converted after absorption to its active neprilysin-inhibiting metabolite, and with most angiotensin-converting enzyme inhibitors: enalapril and ramipril are ester prodrugs requiring hepatic hydrolysis to their active diacid forms. Knowing which drugs in this module require metabolic activation and which do not is part of the classification vocabulary for this drug set.

Correct Answer

D — Neprilysin inhibitor

Rationale

Sacubitril is classified as a neprilysin inhibitor. It is administered as a prodrug and converted after absorption to its active neprilysin-inhibiting metabolite. Neprilysin is a zinc metallopeptidase that cleaves and inactivates natriuretic peptides, bradykinin, and other vasoactive peptides. By inhibiting neprilysin, sacubitril allows these peptides to accumulate and exert their effects. The partner drug valsartan is the angiotensin receptor blocker component of the combination. Phosphodiesterase inhibitors and direct renin inhibitors are separate drug classes entirely.

Correct Answer

B — AT1 receptor

Rationale

Angiotensin receptor blockers are classified as selective angiotensin type 1 receptor antagonists. The AT1 receptor mediates the primary physiological and pathological effects of angiotensin II: vasoconstriction, aldosterone secretion, sodium and water retention, and cardiac and vascular remodeling. Angiotensin receptor blockers block this receptor selectively, leaving the AT2 receptor unoccupied. The mineralocorticoid receptor is the target of aldosterone antagonists such as spironolactone, not of angiotensin receptor blockers.

Correct Answer

C — Sacubitril

Rationale

Sacubitril is classified as a prodrug. After oral absorption, it is hydrolyzed to its active neprilysin-inhibiting metabolite, which is responsible for all pharmacological activity. Losartan, valsartan, and irbesartan are angiotensin receptor blockers that are pharmacologically active as administered and do not require conversion to an active form. Knowing that sacubitril is a prodrug is part of its classification vocabulary in this drug class.

Correct Answer

B — Angiotensin receptor blockers act downstream of angiotensin-converting enzyme and do not affect bradykinin metabolism

Rationale

The cough caused by angiotensin-converting enzyme inhibitors results from bradykinin accumulation: blocking angiotensin-converting enzyme prevents bradykinin degradation, and the accumulated bradykinin sensitizes pulmonary sensory fibers. Angiotensin receptor blockers block the AT1 receptor directly, downstream of angiotensin-converting enzyme. Because they do not inhibit angiotensin-converting enzyme, bradykinin continues to be degraded normally and levels do not rise. Angiotensin receptor blockers reduce angiotensin II effects but do not block angiotensin II production — angiotensin-converting enzyme remains active and continues generating angiotensin II, which circulates but cannot bind its blocked receptor.

Correct Answer

D — Reduced angiotensin II activity decreases aldosterone secretion, reducing potassium excretion at the collecting duct

Rationale

Angiotensin receptor blockers block the AT1 receptor on the adrenal cortex, reducing angiotensin II-stimulated aldosterone secretion. Aldosterone normally acts on the collecting duct principal cells to promote sodium reabsorption and potassium excretion. With less aldosterone, potassium excretion falls and plasma potassium rises. This mechanism is identical to that of angiotensin-converting enzyme inhibitors — both classes reduce aldosterone through suppression of the renin-angiotensin system, just at different steps. Bradykinin is not involved in angiotensin receptor blocker-associated hyperkalemia.

Correct Answer

A — Inhibition of neprilysin prevents degradation of natriuretic peptides, raising their circulating levels and amplifying their vasodilatory and natriuretic effects

Rationale

Neprilysin is a zinc metallopeptidase that normally cleaves and inactivates natriuretic peptides including atrial natriuretic peptide and brain natriuretic peptide. In heart failure, the ventricles secrete large amounts of brain natriuretic peptide as a compensatory response, but neprilysin limits how high these levels can rise. Sacubitril inhibits neprilysin, preventing natriuretic peptide degradation and allowing them to accumulate. The elevated natriuretic peptide levels then activate their receptors, producing vasodilation, natriuresis, and suppression of aldosterone — all beneficial in heart failure. Sacubitril does not directly activate receptors or inhibit phosphodiesterase.

Correct Answer

C — Sacubitril inhibits neprilysin-mediated bradykinin degradation while angiotensin-converting enzyme inhibitors simultaneously reduce angiotensin-converting enzyme-mediated bradykinin degradation, causing additive bradykinin accumulation and angioedema risk

Rationale

Bradykinin is normally degraded by two separate enzymes: angiotensin-converting enzyme and neprilysin. When an angiotensin-converting enzyme inhibitor blocks one degradation pathway and sacubitril simultaneously blocks the other, bradykinin accumulates to levels that can cause severe, potentially fatal angioedema. This additive pharmacodynamic interaction at the level of bradykinin degradation is the mechanistic basis for the absolute contraindication. Hyperkalemia is a shared adverse effect but is not the basis for the absolute contraindication. Valsartan blocks the AT1 receptor while angiotensin-converting enzyme inhibitors act at a separate enzymatic step upstream — these are distinct sites of action with no pharmacokinetic competition between them.

Correct Answer

B — Sacubitril and its active metabolite have a prolonged tissue half-life; starting too soon after lisinopril allows both bradykinin degradation pathways to be blocked simultaneously, creating severe angioedema risk

Rationale

A mandatory 36-hour washout period is required when transitioning in either direction between an angiotensin-converting enzyme inhibitor and sacubitril-valsartan. The reason is pharmacokinetic and mechanistic: sacubitril and its active metabolite have a prolonged tissue half-life, meaning that simply stopping one drug and starting the other the same day leaves both active in the body simultaneously. When both are present together, angiotensin-converting enzyme-mediated and neprilysin-mediated bradykinin degradation are both blocked, and bradykinin accumulates to levels that can cause severe or fatal angioedema. The 36-hour washout ensures sacubitril or the angiotensin-converting enzyme inhibitor has cleared sufficiently before the other is introduced.

Correct Answer

D — Sacubitril inhibits neprilysin, which normally degrades brain natriuretic peptide, so brain natriuretic peptide accumulates regardless of disease severity

Rationale

Neprilysin is one of the primary enzymes that degrades brain natriuretic peptide in the circulation. When sacubitril inhibits neprilysin, brain natriuretic peptide is no longer cleared at its normal rate and accumulates — not because the heart is producing more, but because degradation is impaired. Brain natriuretic peptide levels therefore rise artifactually in patients taking sacubitril-valsartan and cannot be used to assess heart failure severity or treatment response. NT-proBNP, the inactive amino-terminal cleavage fragment of brain natriuretic peptide, is not a neprilysin substrate and continues to reflect actual ventricular wall stress accurately. NT-proBNP is the correct biomarker to follow in patients on sacubitril-valsartan.

Correct Answer

A — Natriuretic peptide receptor activation is coupled to guanylate cyclase, increasing intracellular cyclic GMP and relaxing vascular smooth muscle

Rationale

Natriuretic peptide receptors are membrane-bound guanylate cyclases. When atrial natriuretic peptide or brain natriuretic peptide binds, the receptor's intrinsic guanylate cyclase activity is activated, converting GTP to cyclic guanosine monophosphate. Elevated cyclic GMP activates protein kinase G, which relaxes vascular smooth muscle (producing vasodilation), promotes natriuresis and diuresis in the kidney, and suppresses aldosterone secretion. This cyclic GMP-based signaling is distinct from the cyclic AMP-based signaling of beta adrenergic receptors and from calcium-based ion channel signaling.

Correct Answer

C — Additive suppression of angiotensin II and aldosterone increases rates of acute kidney injury, hyperkalemia, and hypotension without reducing cardiovascular outcomes compared to either agent alone

Rationale

The ONTARGET trial compared telmisartan alone, ramipril alone, and their combination in high-risk patients. The combination produced more acute kidney injury, hyperkalemia, and hypotension than either agent alone, but did not reduce cardiovascular events or mortality. The harm arises from additive pharmacodynamic suppression of the renin-angiotensin-aldosterone system at two steps simultaneously — the angiotensin-converting enzyme inhibitor blocks angiotensin II production while the angiotensin receptor blocker blocks its action — producing greater hemodynamic and renal consequences than either alone. Bradykinin is elevated by the angiotensin-converting enzyme inhibitor component, but the primary basis for the contraindication is pharmacodynamic harm without benefit, not bradykinin effects.

Correct Answer

D — The cough was bradykinin-mediated and resolved because angiotensin receptor blockers do not affect bradykinin metabolism; hyperkalemia persists because it results from reduced aldosterone — a shared consequence of blocking angiotensin II effects in both drug classes

Rationale

This question tests the key mechanistic distinction between bradykinin-dependent and angiotensin II-dependent adverse effects of renin-angiotensin-aldosterone system blockers. The cough is driven exclusively by bradykinin accumulation — a consequence unique to angiotensin-converting enzyme inhibitors. Angiotensin receptor blockers do not inhibit angiotensin-converting enzyme, so bradykinin is degraded normally and the cough resolves. Hyperkalemia, by contrast, results from reduced angiotensin II activity at the AT1 receptor on the adrenal cortex, suppressing aldosterone secretion and reducing potassium excretion at the collecting duct. Both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce angiotensin II effects and both therefore suppress aldosterone, making hyperkalemia a shared class effect that persists after switching.

Correct Answer

B — Sacubitril-valsartan simultaneously inhibits neprilysin to amplify the heart's own natriuretic peptide response while blocking AT1 receptors, addressing both pathological renin-angiotensin-aldosterone activation and impaired compensatory natriuretic signaling

Rationale

Sacubitril-valsartan has a dual mechanism that enalapril alone cannot replicate. The sacubitril component inhibits neprilysin, preventing natriuretic peptide degradation and amplifying the beneficial compensatory natriuretic peptide response the failing heart generates. The valsartan component blocks the AT1 receptor, suppressing the pathological renin-angiotensin-aldosterone activation that drives disease progression. The PARADIGM heart failure trial demonstrated that this combination reduced cardiovascular death and heart failure hospitalization by 20 percent relative to enalapril in patients with heart failure with reduced ejection fraction. Sacubitril-valsartan replaces rather than adds to angiotensin-converting enzyme inhibitor therapy. Adherence and cough avoidance are practical advantages; the mechanistic rationale is the dual amplification of natriuretic peptide signaling combined with angiotensin II blockade.

Correct Answer

A — Sacubitril raises natriuretic peptide levels producing vasodilation while valsartan reduces angiotensin II-mediated vasoconstriction, and the combined vasodilatory effect is most pronounced at initiation before physiological adaptation occurs

Rationale

Sacubitril-valsartan produces vasodilation through two complementary mechanisms simultaneously: sacubitril inhibits neprilysin, allowing natriuretic peptides to accumulate and act on vascular smooth muscle to produce vasodilation, while valsartan blocks AT1 receptors and removes angiotensin II-driven vasoconstriction. In a patient with heart failure whose systemic vascular resistance is already reduced, this dual vasodilatory effect can precipitate symptomatic hypotension, particularly at initiation before compensatory mechanisms adapt. The correct management is dose reduction and slower up-titration — not discontinuation, since the drug confers mortality benefit. Bradykinin is raised by sacubitril, but its vasodilatory contribution occurs through endothelial nitric oxide pathways rather than being the primary explanation for initiation hypotension. Valsartan blocks AT1, not AT2 receptors.

Correct Answer

C — Sacubitril-valsartan should be used with caution or avoided in this patient because sacubitril inhibits neprilysin-mediated bradykinin degradation, raising bradykinin in a patient already demonstrated to be susceptible to bradykinin-driven angioedema

Rationale

Angiotensin-converting enzyme inhibitor-induced angioedema is bradykinin-mediated, not histamine-mediated. Bradykinin accumulates because angiotensin-converting enzyme — one of the enzymes that degrades bradykinin — is blocked. Sacubitril inhibits neprilysin, a separate enzyme that also degrades bradykinin. In a patient who developed angioedema from elevated bradykinin on an angiotensin-converting enzyme inhibitor, adding sacubitril — which raises bradykinin through a different but parallel pathway — carries meaningful risk of recurrent angioedema. This is a qualitatively different concern from the absolute contraindication of combining sacubitril-valsartan with an angiotensin-converting enzyme inhibitor simultaneously; here the concern is the patient's established bradykinin hypersensitivity. Sacubitril-valsartan is not automatically safe simply because it lacks an angiotensin-converting enzyme inhibitor component. Prior angioedema history does not resolve with time, and antihistamines are ineffective for bradykinin-mediated angioedema.